The partnership will explore the use of AI to predict the effectiveness of neoadjuvant therapy, a form of chemotherapy, in locally advanced breast cancer.
Baheya Foundation has announced a partnership with General Electric Healthcare to develop the use of Artificial Intelligence in the fight against cancer. The partnership will explore the use of AI to predict the effectiveness of neoadjuvant therapy, a form of chemotherapy, in locally advanced breast cancer.
Typically, neoadjuvant therapy is useful in reducing the size of a cancerous tumour before surgery. The AI will be able to give clinicians an earlier sign that the patient isn't responding to the treatment, giving them the chance to change the treatment as early as possible before the patient experiences unnecessary toxicity while reducing the treatment costs for the hospital.
Established in 2015, the Baheya Foundation and its Cairo hospital - formerly the home of Baheya Wahbi, whose children founded the organisation to honour her request to make world-class treatments more accessible to Egyptian women - is dedicated to providing free diagnosis and treatments to women.
They currently perform 7,000 early detection tests and 1,500 chemotherapy sessions a month, as well as 3,000 radiation therapy sessions and 350 surgeries a month. They are also in the process of building another hospital in Sheikh Zayed, which is expected to open in 2023.